MRI Evaluation of Breast Tumor Growth and Treatment Response
- Develop and combine advanced, quantitative, multiparametric magnetic resonance imaging
methods (i.e., dynamic contrast-enhanced MRI [DCE-MRI], diffusion-weighted MRI
[DW-MRI], and magnetic resonance spectroscopy [MRS]) to characterize breast tumors in
women with known or suspected breast cancer.
- Identify surrogate biomarkers that can guide diagnosis and treatment of breast cancer
using these methods.
- Correlate biochemical information obtained from magnetic resonance analysis with
clinical, radiologic, and pathologic findings in these patients.
- Establish an imaging data bank that includes information on DCE-MRI, DW-MRI, and MRS
findings in these patients and in healthy participants.
OUTLINE: Quantitative, multi-parametric magnetic imaging methods will be employed for
breast imaging for the following subjects:
- Group A: Healthy volunteers who undergo up to 3 breast MRIs over 6 weeks.
- Group B: Patients diagnosed with breast cancer who will: 1) undergo preoperative breast
MRI followed by definitive surgery or 2) undergo MRI prior to initiating neoadjuvant
chemotherapy, at 1-2 weeks after initiation of chemotherapy, and prior to definitive
Clinical information, including radiologic and pathologic data, on all patients is collected
for inclusion in the imaging data bank.
After completion of the study, patients and healthy participants are followed periodically.
Observational Model: Cohort, Time Perspective: Prospective
Feasibility of advanced, quantitative, multi-parametric magnetic resonance imaging (MRI) methods for characterizing breast tumors to develop potential surrogate imaging markers for diagnosis and prediction of treatment response
Quantitative, multi-parametric MRI imaging methods include Dynamic Contrast MRI, Diffusion Weighted MRI, and Magnetic Resonance Spectroscopy. Patients will include healthy female volunteers and women diagnosed with breast cancer
at study entry (healthy volunteers), pre-surgical and pre- and post-chemotherapy (breast cancer patients)
A. Bapsi Chakravarthy, MD
Vanderbilt-Ingram Cancer Center
United States: Food and Drug Administration
VICC BRE 0588
|Vanderbilt-Ingram Cancer Center||Nashville, Tennessee 37232-6838|
|Vanderbilt-Ingram Cancer Center - Cool Springs||Nashville, Tennessee 37064|
|Vanderbilt-Ingram Cancer Center at Franklin||Nashville, Tennessee 37064|